2024
Discordances Between Radiology and Pathology
Harigopal M, Verma A, Andrejeva L, Lewin J. Discordances Between Radiology and Pathology. 2024, 375-391. DOI: 10.1007/978-3-031-65711-5_14.Peer-Reviewed Original ResearchPathological findingsImaging characteristicsMRI-guided biopsyFalse-negative diagnosesRadiology-pathology correlationH&E levelsPreoperative biopsyStereotactic biopsySurgical excisionPercutaneous biopsyDiscordant casesSonographic guidanceBreast biopsyAncillary stainsHistopathological findingsBiopsyMammographic lesionsLesionsIndividual pathologistsPathologistsPotential causesUltrasoundWeekly conferencesImage featuresDiscordanceConventional and Contrast-enhanced US of the Lung: From Performance to Diagnosis.
Jiménez-Serrano S, Páez-Carpio A, Doménech-Ximenos B, Cornellas L, Sánchez M, Revzin M, Vollmer I. Conventional and Contrast-enhanced US of the Lung: From Performance to Diagnosis. RadioGraphics 2024, 44: e230171. PMID: 38935548, DOI: 10.1148/rg.230171.Peer-Reviewed Original ResearchConceptsPeripheral lung diseaseContrast-enhanced USDiagnosis of peripheral lung diseasePercutaneous biopsyLung USEnhancement patternLung diseaseImage-guided percutaneous biopsyAccurate differential diagnosisDiagnostic chest imagingLung biopsySubpleural lesionsConventional USDifferential diagnosisPathological findingsPulmonary physiologyChest imagingArterial supplyBiopsyLungDiagnostic testsDiagnosisSoft tissueDiseaseImaging time
2022
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings
Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Lederman RI, Frank E, Sohl JJ, Stadler ZK, Erick TK, Peppercorn J, Winer EP, Silverman SG, Come SE, Lin NU. Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Research And Treatment 2022, 192: 201-210. PMID: 35066788, DOI: 10.1007/s10549-021-06494-z.Peer-Reviewed Original ResearchConceptsAdditional biospecimensMedical oncologistsBreast biopsyBreast tissueBiopsy resultsSingle academic medical centerBreast medical oncologistsPain/discomfortPerceptions of patientsMost medical oncologistsAbnormal breastDiagnostic breast biopsyAcademic medical centerPercutaneous breast biopsyNational Cancer InstituteDonation of bloodCancer CenterDiagnostic biopsyPercutaneous biopsyMedical CenterBiopsyCancer InstitutePatientsOncologistsProcedure risk
2018
Breast Ultrasound Overview
Raghu M, Philpotts L. Breast Ultrasound Overview. 2018, 72-80. DOI: 10.1093/med/9780190270261.003.0008.Peer-Reviewed Original Research
2017
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramanathan R, Weiss G, Posner R, Rajeshkumar N, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites E, Hlavacek W, Gatalica Z, Xiu J, Hidalgo M, Von Hoff D, Barrett M. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal Of Gastrointestinal Oncology 2017, 8: 925-935. PMID: 29299351, PMCID: PMC5750179, DOI: 10.21037/jgo.2017.09.05.Peer-Reviewed Original ResearchMetastatic pancreatic cancer patientsPancreatic cancer patientsCancer patientsNon-cross-resistant regimensExcision repair cross-complementation group 1 proteinPhase II studyPhase 2 trialEfficacy of therapyBased treatment strategiesImmunohistochemistry targetingInsufficient tumorStudy therapyLine therapyMedian survivalCytotoxic therapyMetastatic lesionsCancer related symptomsTumor biopsiesII studyPercutaneous biopsyTumor immunohistochemistryTreatment regimensTreatment strategiesBiopsyRegimens
2012
Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium
Ramanathan R, Barrett M, Weiss G, Posner R, NV R, Jameson G, Demeure M, Hoering A, Stites E, Maitra A, Fulk M, Hidalgo M, Von Hoff D. Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium. Cancer Research 2012, 72: lb-221-lb-221. DOI: 10.1158/1538-7445.am2012-lb-221.Peer-Reviewed Original ResearchMetastatic pancreatic cancerPhase II studyMolecular profilingPercutaneous biopsyPerformance statusPancreatic cancerNon-cross-resistant regimenOutcome of salvage therapyPatients treated with FOLFIRIRefractory metastatic pancreatic cancerMetastatic pancreatic cancer patientsSurvival rateTreating metastatic pancreatic cancerAdequate bone marrowAdequate performance statusAneuploid tumour cell populationsYear survival rateAmerican Association for Cancer ResearchEfficacy of therapyFactors of patientsTumor cell populationLong-term survivalInsufficient tumorSalvage therapyStudies of therapy
2005
Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma
Cillo U, Vitale A, Navaglia F, Basso D, Montin U, Bassanello M, D'Amico F, Ciarleglio F, Brolese A, Zanus G, De Pascale V, Plebani M, D'Amico D. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World Journal Of Gastroenterology 2005, 11: 6920-6925. PMID: 16437593, PMCID: PMC4717031, DOI: 10.3748/wjg.v11.i44.6920.Peer-Reviewed Original ResearchConceptsTumor gradeHepatocellular carcinomaRadical therapyAFP mRNASurgical therapyMRNA statusPrognostic evaluation of HCC patientsAssessment of tumor gradePrognostic evaluation of patientsDiagnosis of hepatocellular carcinomaNodule sizeDetermination of tumor gradeEvaluation of HCC patientsPreoperative tumor gradeMedian follow-upPercutaneous ablative proceduresTumor-related variablesSignificant survival predictorsPotential prognostic roleCohort of patientsEvaluation of patientsSignificant prognosticatorsPrognostic rolePercutaneous biopsyPerformance status
1975
Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata.
Chabner B, Johnson R, Chretien P, Schein P, Young R, Canellos C, Hubbard S, Anderson T, Rosenoff S, DeVita V. Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata. British Journal Of Cancer. Supplement 1975, 2: 242-7. PMID: 126693, PMCID: PMC2149568.Peer-Reviewed Original ResearchConceptsPercutaneous liver biopsyLiver biopsyLymphocytic lymphomaUntreated patientsHodgkin's lymphomaPercutaneous liver biopsy specimensStage IV diseaseConsecutive untreated patientsWedge liver biopsyLiver biopsy specimensLiver involvementPositive biopsiesBiopsy specimensPercutaneous biopsyLaparotomyPatientsBiopsyLymphomaPositive findingsTwo-thirdsFindingsDiseaseLiver
1973
Diagnosis of liver involvement by lymphoma: Results in 96 consecutive peritoneoscopies
Bagley C, Thomas L, Johnson R, Chretien P, Devita V. Diagnosis of liver involvement by lymphoma: Results in 96 consecutive peritoneoscopies. Cancer 1973, 31: 840-847. PMID: 4267529, DOI: 10.1002/1097-0142(197304)31:4<840::aid-cncr2820310412>3.0.co;2-w.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseHepatic involvementLiver biopsyPositive biopsiesHodgkin's lymphomaLymphocytic lymphomaMultiple liver biopsiesMultiple needle biopsiesPresence of hepatomegalyLiver function testsPercutaneous liver biopsyUntreated Hodgkin's diseaseFrequent false-negative resultsPresence of symptomsFalse-negative resultsLiver involvementNodal diseaseWedge biopsyLymphomatous involvementFunction testsMinimal morbidityNeedle biopsyPercutaneous biopsySame patientBiopsy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply